...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives
【24h】

Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives

机译：甘精胰岛素300 U / ml用于糖尿病的治疗：临床实用性和患者观点

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is ongoing interest in optimizing basal insulin treatment by developing insulins with a flat pharmacological profile, a long duration of action (typically beyond 24 hours) and minimum day-to-day variation. Glargine-300 is a modified form of the long-acting insulin analog glargine in that it has been concentrated at 300 units/mL rather than the conventional 100?units/mL. Glargine-300 has a longer duration of action and a flatter pharmacological profile than original?glargine-100. This property allows for more flexibility around the timing of administration, when injected once per day. Open-label studies in patients with diabetes have shown that treatment with glargine-300 achieves comparable glycemic control compared to treatment with glargine-100, albeit with consistently higher insulin requirements. These studies also showed that treatment with glargine-300 was associated with lower risks of nocturnal hypoglycemia in patients with type 2 diabetes, particularly those already on insulin, whereas data are mixed in insulin-na?ve patients with type 2 diabetes or in patients with type 1 diabetes. Treatment with glargine-300 did not appear to affect the risk of overall hypoglycemia, whereas studies lacked sufficient power to investigate the effect on the risk of severe hypoglycemia. Future studies need to establish the role of glargine-300 in the treatment of diabetes alongside the other new long-acting insulin analog, insulin degludec, which was recently introduced to the market.
机译：通过开发具有平坦药理学特征，作用时间长（通常超过24小时）和每日变化最小的胰岛素来优化基础胰岛素治疗一直存在着人们的兴趣。 Glargine-300是长效胰岛素类似物甘精胰岛素的改良形式，其浓缩浓度为300单位/ mL，而不是常规的100？单位/ mL。甘精胰岛素300的作用时间比原始甘精胰岛素100更长，药理作用更平坦。每天注射一次时，此特性可在给药时机上提供更大的灵活性。在糖尿病患者中进行的开放标签研究表明，与甘精胰岛素100相比，甘精胰岛素300的治疗可达到相当的血糖控制，尽管胰岛素需求持续较高。这些研究还表明，在患有2型糖尿病的患者中，尤其是已经接受胰岛素治疗的患者，用glargine-300进行治疗可降低夜间低血糖的风险，而对于初次使用胰岛素的2型糖尿病患者或患有2型糖尿病的患者，数据混杂1型糖尿病。 glargine-300的治疗似乎并未影响总体低血糖的风险，而研究缺乏足够的能力来研究对严重低血糖风险的影响。未来的研究需要确定甘精氨酸300在糖尿病治疗中的作用，以及最近新推向市场的其他新的长效胰岛素类似物胰岛素脱地德胰岛素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号